UMIN-CTR Clinical Trial

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000030240
Receipt No. R000034540
Scientific Title Randomized phase 3 trial evaluating the efficacy of ICG fluorescence imaging on anastomotic leakage in laparoscopic surgery of rectal cancer.
Date of disclosure of the study information 2018/04/01
Last modified on 2022/12/12 (Ver. 10)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Randomized phase 3 trial evaluating the efficacy of ICG fluorescence imaging on anastomotic leakage in laparoscopic surgery of rectal cancer.
Acronym EssentiAL study
Scientific Title Randomized phase 3 trial evaluating the efficacy of ICG fluorescence imaging on anastomotic leakage in laparoscopic surgery of rectal cancer.
Scientific Title:Acronym EssentiAL study
Region
Japan

Condition
Condition Rectal cancer
Classification by specialty
Surgery in general Gastrointestinal surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 The aim of this study is to clarify the usefulness of blood flow evaluation by near infrared imaging using indocyanine green (ICG) as prevention of anastomotic leak after rectal anterior resection for rectal cancer by randomized controlled trial.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Anastomotic leakage rate
Key secondary outcomes Anastomotic leakage rate(Grade B+C)
Fluorescence time at the oral side anastomotic site
Rate of the additional transection of the proximal colon toward the oral side
Length of the additional transection of the proximal colon toward the oral side
Rates of complications within 30 days after surgery
Rates of complications during surgery
Reoperation rate
Postoperative hospital stay

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control No treatment
Stratification YES
Dynamic allocation
Institution consideration Institution is considered as adjustment factor in dynamic allocation.
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Medicine
Interventions/Control_1 Evaluation of blood flow by near infrared imaging using indocyanine green
Interventions/Control_2 control
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >=
Gender Male and Female
Key inclusion criteria 1. Patients who are histologically proven to be rectal cancer
2. The lower edge of the tumor is within 12 cm from the anal margin
3. Patients diagnosed with Stage 0-3 in preoperative diagnostic imaging
4. Patients who are scheduled for rectal resection with intestinal anastomosis (including ISR)
5. Patients with General State Performance Status (ECOG) 0 to 2
6. Patients whose age at registration is 20 years or older
7. Patients whose functions of the main organs are adequately maintained and judged to be safe for surgery by the doctor in charge of examination
1 White blood cell count> 3,000 / mm 3
2 platelet> 100,000 / mm 3
3 GOT <100 IU / L
4 GPT <100 IU / L
5 Total bilirubin <2.0 mg / dl
6 Cr <2.0 mg / dl

8. About participation in this study Patients who have obtained consent from a document stating signature and date by the applicant
Key exclusion criteria 1. Patients who are allergic to iodine or indocyanine green
2. Preoperative intestinal obstruction patients
3. Patients planning simultaneous resection of other organs due to double cancer
4. Patients scheduled to anastomosis at more than two sites due to multiple colon cancer
5. Patients with intraperitoneal infection (peritonitis or abdominal abscess)
6. Patients with serious complications (heart disease, lung disease, bleeding tendency, poorly controlled hypertension, diabetes etc.)
7. Pregnancy and patients with fear thereof
8. Other patients judged inappropriate by the examining physician
Target sample size 850

Research contact person
Name of lead principal investigator
1st name Ichiro
Middle name
Last name Takemasa
Organization Sapporo Medical University
Division name Department of Surgery, Surgical Oncology and Science
Zip code 060-8556
Address Nishi 17, Minami 1 jyo, Cyuou-ku, Sapporo
TEL 0116112111
Email itakemasa@sapmed.ac.jp

Public contact
Name of contact person
1st name Jun
Middle name
Last name Watanabe
Organization Yokohama City University Medical Center
Division name Department of surgery
Zip code 232-0024
Address Urafune-cho 4-57 Minami-ku Yokohama
TEL 045-261-5656
Homepage URL
Email jun0926@yokohama-cu.ac.jp

Sponsor
Institute Sapporo Medical University
Institute
Department

Funding Source
Organization Stryker Japan K.K.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Yokohama City University Certified Review Board
Address 5F, 1-1-1, Fukuura, Kanazawa-ku, Yokohama
Tel 046-261-5656
Email jun0926@yokohama-cu.ac.jp

Secondary IDs
Secondary IDs YES
Study ID_1 CRB3180007
Org. issuing International ID_1 Yokohama City University Certified Review Board
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 04 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2017 Year 12 Month 04 Day
Date of IRB
2018 Year 09 Month 07 Day
Anticipated trial start date
2018 Year 11 Month 01 Day
Last follow-up date
2021 Year 12 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 12 Month 04 Day
Last modified on
2022 Year 12 Month 12 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000034540